Research Cluster

Weight Loss & Metabolic Peptides

This cluster contains the most extensively studied and highest-traffic compounds on Peptidings. Semaglutide and tirzepatide are FDA-approved drugs backed by Phase III trial programs involving tens of thousands of participants. They sit on the same page as 5-Amino-1MQ, which has no published human data at all. That range is not an editorial inconsistency—it reflects the actual state of the metabolic peptide research landscape, and understanding the distance between these compounds is the central value of reading this cluster carefully.
The mechanistic story of this cluster is incretin biology—the GLP-1 receptor agonists that began with liraglutide and now extend to triple-agonist compounds targeting GLP-1, GIP, and glucagon simultaneously. Understanding that lineage is the key to understanding why the evidence for semaglutide does not transfer to AOD-9604, and why the clinical data for tirzepatide is not a proxy for retatrutide.

Cluster at a Glance
10 Compounds
3
FDA-approved
4
Active Phase II/III trials
3
Preclinical or limited human data

4Preclinical Only

5-Amino-1MQ: What the Research Shows

NNMT-inhibiting small molecule studied for fat loss and metabolic improvement. Preclinical evidence only.
Read the research →

Clinical Trials

AOD-9604: The Growth Hormone Fragment That Failed Its Only Clinical Trial

hGH fragment 176-191. Phase IIb oral trial (n=300) failed primary endpoint—no significant weight loss vs placebo. GRAS for food ingredient use is not drug approval.
Read the research →

Clinical Trials

CagriSema: What the Research Shows

Combination GLP-1/amylin receptor agonist studied for weight loss and glucose control. Phase III trials ongoing.
Read the research →

Approved DrugWADA

Liraglutide (Victoza / Saxenda): What the Research Shows

FDA-approved GLP-1 receptor agonist for type 2 diabetes and obesity. Extensive clinical trial evidence.
Read the research →

Clinical Trials

Orforglipron: What the Research Shows

Oral non-peptide GLP-1 receptor agonist studied for weight loss and glucose control. Phase III trials ongoing.
Read the research →

Clinical Trials

Retatrutide: What the Research Shows

Triple GLP-1R/GIPR/GcgR agonist studied for weight loss, showing the largest reductions in Phase II trials to date.
Read the research →

Approved DrugWADA

Semaglutide (Ozempic / Wegovy): What the Research Shows

FDA-approved GLP-1 receptor agonist for type 2 diabetes and obesity. Available as Ozempic and Wegovy.
Read the research →

Clinical Trials

Survodutide: What the Research Shows

Dual GLP-1R/GcgR agonist studied for weight loss and NASH. Phase II/III trials ongoing.
Read the research →

Approved DrugWADA

Tirzepatide (Mounjaro / Zepbound): What the Research Shows

FDA-approved dual GLP-1R/GIPR agonist for type 2 diabetes and obesity. Available as Mounjaro and Zepbound.
Read the research →

How These Compounds Relate

The approved compounds in this cluster—liraglutide, semaglutide, and tirzepatide—represent three generations of incretin therapy. Liraglutide established the GLP-1 receptor agonist class as a viable weight loss approach. Semaglutide doubled the efficacy and extended to weekly dosing and oral administration. Tirzepatide added GIP agonism and pushed mean weight loss above 20%.

The pipeline compounds—retatrutide, cagrisema, orforglipron, and survodutide—each represent a distinct hypothesis about what comes after tirzepatide: adding glucagon agonism for greater energy expenditure (retatrutide, survodutide), combining incretin with amylin signaling for a different receptor profile (cagrisema), or abandoning the peptide format entirely for a small molecule oral (orforglipron).

AOD-9604 and 5-Amino-1MQ sit entirely outside the incretin lineage. AOD-9604 is an hGH fragment with a failed primary efficacy endpoint in its one Phase IIb trial. 5-Amino-1MQ is an NNMT inhibitor with no human data at all. Their inclusion in self-experimentation weight loss stacks alongside GLP-1 agonists is not pharmacologically coherent—these compounds target different pathways, and the evidence for stacking them has not been evaluated.

Understanding the incretin lineage is the prerequisite for evaluating anything else in this cluster. Read the semaglutide and tirzepatide articles first.

The Research Digest

Weekly peptide science without the noise. New studies, honest methodology breakdowns, and what the literature still doesn’t answer.

Subscribe on Substack →

Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.

Scroll to Top